About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, April 8th, 2014

The QualityStocks
Daily Stock List


Sunshine Biopharma, Inc. (SBFM)

PennyStockSpy reported yesterday on Sunshine Biopharma, Inc. (SBFM), Ironman Stock, Investor Ideas did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Sunshine Biopharma, Inc. is a pharmaceutical company focusing on the research, development, and commercialization of drugs for the treatment of different forms of cancer.  The Company’s dedication is to developing novel therapies for the treatment of various forms of aggressive cancer types.  Their initial drug candidate, Adva-27a, is a small molecule, which has proven effective against different types of multidrug resistant cancer cell lines. These include breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR), uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1). Sunshine Biopharma has their corporate headquarters in Montreal, Quebec.

The Company’s Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer.  Adva-27a is now in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.

In January 2011, Sunshine Biopharma entered into a collaboration agreement with Binghamton University (State University of New York at Binghamton, New York). This agreement is to conduct certain research and development activities intended at advancing the Company’s lead compound, Adva-27a, through various stages of preclinical development.

In June 2011, the Company entered into a Clinical Trials Agreement with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct certain research and development activities and advance Sunshine’s lead compound, Adva-27a, through the different stages of preclinical studies and Phase I clinical trials on multidrug resistant breast cancer patients. Sunshine Biopharma is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal.

Yesterday, Sunshine Biopharma announced that they resolved the two isomeric forms of their lead anticancer compound, Adva-27a, and accordingly the specific activity of the drug candidate has increased 9.5-fold. The Company had previously announced that the concentration at which Adva-27a inhibited 50 percent of the activity of Topoisomerase II (IC50) was 13.7 micromolar. Because of yesterday's development Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. Sunshine Biopharma said that this suggests that significantly lower quantities of the drug can be used to achieve the same effect.

Sunshine Biopharma, Inc. (SBFM), closed Tuesday's trading session at $0.20, down 13.08%, on 389,505 volume with 80 trades. The average volume for the last 60 days is 93,032 and the stock's 52-week low/high is $0.102/$0.33.

Tiger Oil and Energy, Inc. (TGRO)

Market Authority, SmallCapInvestorDaily, Pumps and Dumps, PennyStocks24, Stock Tips, and Penny Stock Rumble reported earlier on Tiger Oil and Energy, Inc. (TGRO), and we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

Tiger Oil and Energy, Inc. is a diversified oil exploration company whose shares trade on the OTCQB. The Company is expanding their portfolio of projects with value added acquisitions and participations. Tiger Oil and Energy engages in the exploration, development, and production of oil and gas fields. The Company previously went by the name UTeC, Inc. They changed their name to Tiger Oil and Energy, Inc. in September of 2010. The Company has their headquarters in Las Vegas, Nevada.

Tiger Oil and Energy previously closed an exchange agreement with Jett Rink Oil, LLC. They acquired 100 percent of Jett Rink Oil. With this purchase, Tiger acquired interests in two oil and gas leases in Creek County, Oklahoma, together with all equipment located within.  Both wells are shut-in and are not producing. Tiger will continue to evaluate shut-in wells in Kansas and Oklahoma with the intention of putting historically productive wells back into production.

Concerning the Oklahoma projects, the Company owns a 7.5 percent working interest (WI) in Shilo #1 with 80 percent net revenue interest (NRI), in the gas and oil lease described as “The N/2 NE/4 of Section 17, Township 16N, Range 10E”, containing approximately 40 acres, in Creek County, Oklahoma.  Additionally, the Company owns an 11.5 percent WI with 80 percent NRI, in the gas and oil lease described as “The SW/4 NW/4 NE/4 of Section 17, Township 16N, Range 10E”, containing approximately 10 acres, in Creek County, Oklahoma - the Shilo #2.

In December 2013, Tiger Oil and Energy announced that they signed an election to participate in the first of three wells with TOTO Energy LLC (a Texas oil and gas producer) in Cowley County, Kansas. Tiger will earn a 30 percent WI and a 24.45 percent NRI in the well.  The cost of the first well increased to $630,000 owing to the cold weather for drilling and fracking each well with Tiger's cost of 30 percent to be $189,000 per well. Toto Energy will be the operator of the wells.  In January, Tiger Oil and Energy announced that the Company received the third tranche from a nonrelated source bringing to Tiger the $600,000 needed to go ahead with the drilling plans for the Cowley County, Kansas leases in partnership with TOTO Energy.

Tiger Oil and Energy, Inc. (TGRO), closed Tuesday's trading session at $0.19, up 26.58%, on 185,314 volume with 44 trades. The average volume for the last 60 days is 341,126 and the stock's 52-week low/high is $0.051/$1.59.

Eyes on the Go, Inc. (AXCG)

Pumps and Dumps, PennyStocks24, WallstreetSurfers, Penny Stocks On Steroids, POSstocks, RockingPennyStocks, MarketWireStocks, Pennystocktweeters.com, PennyStockLaboratory, and PennyStockInformer reported earlier on Eyes on the Go, Inc. (AXCG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in New York City, Eyes on the Go, Inc. is a virtual broadcasting business supplying live and recorded content from top New York City nightlife performance venues. The Company, by way of their Gander.tv, streams this live and recorded video from nightlife venues and events. This provides entertainment, exposure, and revenue opportunities. These all make use of digital marketing and social media support. Eyes on the Go introduced their Gander.tv service in January 2012. Eyes on the Go lists on the OTC Markets’ OTCQB.

Eyes on the Go has developed a proprietary software program that runs on computer platforms at customers' facilities. This streams video images and sound from multiple cameras and microphones or soundboards and makes them available to consumers on the Gander.tv website.  Eyes on the Go’s expectation is that in the future the Company will generate more revenue through promotional programs and venue placement fees, and with select consumer product company sponsorships.
Gander.tv works together with clients to promote awareness, interest, and attendance at venues, shows, and events. The Company builds incremental revenue via pay-per-view, advertising, and sponsorships. Gander.tv's mission is to provide unique and authentic content. The Gander.tv service provides online streaming video and audio images from bars, restaurants, performance spaces, and clubs to consumers through the "Gander.tv” website.

Eyes on the Go produces shorter, digestible clips of 1-5 minutes, in addition to broadcasting live content. These clips feature songs and performance segments that can link back to the original video content as it has been recorded or broadcasted live. This gives the Company the ability to repurpose their content through third party websites.

Last month, Eyes on the Go confirmed that total Internet traffic for January exceeded 4 million page views. Moreover, total visitors to Eyes on the Go’s websites exceeded 1.6 million. Page views and visitors doubled from the previous month. Eyes on the Go is experiencing a major increase in the average viewers per broadcast event. In 2013, individual events were drawing online viewers at 2 or 3 times the number of attendees at the venue. In 2014, the Company is realizing an increase to 5 or 6 times attendees.

Eyes on the Go, Inc. (AXCG), closed Tuesday's trading session at $0.0025, up 47.06%, on 146,629,900 volume with 426 trades. The average volume for the last 60 days is 44,899,427 and the stock's 52-week low/high is $0.0004/$0.002.

Ekso Bionics Holdings, Inc. (EKSO)

InvestorPlace, MonsterStocksPicks, and Stock Stars reported on Ekso Bionics Holdings, Inc. (EKSO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ekso Bionics Holdings, Inc. designs, develops, and commercializes exoskeletons, or wearable robots. These have a variety of potential applications in the medical, military, industrial, and consumer markets. The Company’s lead product is Ekso™. Ekso™ has helped thousands of people living with paralysis take millions of steps not otherwise possible. Ekso Bionics was founded in Berkeley, California in 2005.  The Company is headquartered in Richmond, California.

Exoskeletons are ready-to-wear, battery-powered robots. They are strapped over the user's clothing, enabling individuals to achieve mobility, strength, or endurance not otherwise possible. The Company’s Ekso™ is a robotic exoskeleton used for the rehabilitation of individuals with lower extremity weakness, paralysis or hemiparesis (weakness on one side of the body) owing to such neurological conditions as stroke, spinal cord injury or disease, and traumatic brain injury.

Ekso™ is a wearable bionic suit. It allows individuals with any amount of lower extremity weakness to stand up and walk over ground with a natural, full weight bearing, and reciprocal gait. Walking is achieved by the user’s weight shifts to activate sensors in the device, which initiate steps. Battery-powered motors drive the legs, replacing deficient neuromuscular function.

In February, Ekso Bionics Holdings announced that they recently debuted the first ever 3D printed hybrid exoskeleton robotic suit, in collaboration with 3D Systems (DDD), at a Singularity University event in Budapest. Designers from 3D Systems created personalized three-dimensional elements from multiple 3D scans taken of Ekso Ambassador, Amanda Boxtel.

In late March, Ekso Bionics Holdings announced that co-founder Mr. Russ Angold was named president of the Company's division focused on technology development and future applications, formally named Ekso Labs. Mr. Angold will oversee and build out the division that is responsible for developing intellectual property (IP) through engineering contracts and research grants from government organizations and industrial partners, including the Department of Defense (DOD).

Ekso Bionics Holdings, Inc. (EKSO), closed Tuesday's trading session at $2.60, down 3.70%, on 150,586 volume with 126 trades. The average volume for the last 60 days is 171,938 and the stock's 52-week low/high is $2.25/$8.22.

East Coast Diversified Corp. (ECDC)

PennyStocks24, Wallstreetlivechat, and SmallCapVoice reported previously on East Coast Diversified Corp. (ECDC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

East Coast Diversified Corp. is a holding corporation with a diversified group of technology companies. Their business portfolio includes companies offering technology for logistics and asset management, media entertainment, transportation safety and class attendance monitoring and social media applications. EarthSearch Communications, a GPS service provider, acquired East Coast Diversified in April 2010. Since then, and the acquisition by EarthSearch, East Coast Diversified has embarked on developing as a technology company and creating new products and divisions while improving the EarthSearch product offering to the market. 

East Coast Diversified has developed a group of web assets, consisting of five major proprietary "Software" for the operation and management of their businesses. Their proprietary software includes Vir2o, a Social media platform; GATIS – Global Asset Tracking and Identifications System (Logistics business); and CARAS – Customs And Revenue Authority System (Ports and revenue collection).

The Company’s proprietary software also includes StudentConnect – Student Transportation and Safety technology, and SCAAP – StudentConnect Advertisement Aggregation Platform. StudentConnect launched their school transportation technology division in April of 2013 using East Coast Diversified proprietary wireless communication between GPS and RFID to monitor students getting on or off the school bus. StudentConnect is an East Coast Diversified Company. StudentConnect is an integrated complete student transportation and class attendance management system.
East Coast Diversified previously announced that they filed a provisional patent application with the US Patent and Trademark Office (USPTO) on behalf of the Company's social media business Vir2o. The provisional application includes claims to intellectual property (IP) related to their "JoinMe" technology and other use processes that have undergone development for Vir2o. "JoinMe" allows users on Vir2o to engage interactively. Vir2o is a new social media platform by East Coast Diversified.

Yesterday, StudentConnect, the wholly owned subsidiary of East Coast Diversified, announced that they executed a 5 year agreement with their first school district client in the State of Texas.

Kayode Aladesuyi, Chairman/CEO of East Coast Diversified, said, "Texas is a big state with tremendous opportunity for us. We continue to expand our reach and deploying in as many schools as we can and as fast as we can. The request for StudentConnect continues to grow. We hope to have a good number of schools deployed going into the next school."

East Coast Diversified Corp. (ECDC), closed Tuesday's trading session at $0.0002, down 33.33%, on 319,997,548 volume with 105 trades. The average volume for the last 60 days is 230,151,995 and the stock's 52-week low/high is $0.0001/$0.20.


The QualityStocks
Company Corner


Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0061, up 35.56%, on 36,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 180,192, and its 52-week low/high is $0.004/$0.035.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. and The Alternative Initiate New Brand Development Project

Consorteum Holdings Inc. Forms a New, Wholly Owned Subsidiary

Consorteum Holdings Enters Partnership Agreement With KO Entertainment, Inc.

NutraNomics, Inc. (NNRX)

The QualityStocks Daily Newsletter would like to spotlight NutraNomics, Inc. (NNRX). Today, NutraNomics, Inc. closed trading at $0.0701, up 15.49%, on 167,931 volume with 35 trades. The stock’s average daily volume over the past 60 days is 302,421, and its 52-week low/high is $0.0605/$1.48.

NutraNomics, Inc. (NNRX) is focused on the research and development of nutritional dietary supplements, skin and body care products and transdermal patches. In addition to creating formulas for hundreds of companies, the company has produced and branded its own product lines which are sold through retail and wholesale channels. Additionally the company private labels and does custom manufacturing for several supplement companies in national and international markets.

Nearly all vitamins currently on the market are isolated and/or synthetic. The human body doesn’t recognize these types of vitamins and as a result cannot absorb them because they are either missing critical nutritional components or are not food based. NutraNomics has rapidly grown its business over the past 18 years by offering superior food and plant-based products blended from the highest quality sources available for maximum bioavailability.

Today NutraNomics has sales teams in seven different countries promoting its diversified line of wholefood-based supplements, specialty formulas, and remedies. All facilities used to produce the gluten-free, non-GMO nutritional products are cGMP Compliant and FDA approved. To ensure the highest purity potency and quality, the company takes it another step forward by performing additional content testing on all raw materials used to manufacture its products.

NutraNomics is more than just a health supplement provider. As a company dedicated to supporting the worldwide community of people who want to live healthy, NutraNomics is making an impact on those who are suffering from various types of diseases that need specialized diet to enhance their lifestyle. To fulfill this mission NutraNomics has invested in clinical studies for controlling diabetes, heart disease and cancer with dietary supplements. Strong growth is anticipated to continue as the company continues to introduce cutting-edge products and taps into new markets. Disclaimer

NutraNomics, Inc. Company Blog

NutraNomics, Inc. News:

Nutranomics Discusses Long-Term Global Expansion Strategy with UNO International Corp.

Nutranomics Receives Initial Purchase Order from Leading Health Products Distributor in the Philippines

Nutranomics Announces Exclusive Shareholder Product Promotion

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.075, up 19.05%, on 7,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 17,703, and its 52-week low/high is $0.041/$0.29.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Investments Announces Results for Fiscal Year 2013

GlobalWise Announces Its MarketCommand™ Launch

GlobalWise Investments Reports Financial Results for Third Quarter 2013

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.4599, up 48.83%, on 4,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,628, and its 52-week low/high is $0.25/$0.90.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Provides Update on $36 Million Strategic Financing Agreement

VistaGen Therapeutics Presents CardioSafe 3D and LiverSafe 3D Developments at International Society of Stem Cell Research's 11th Annual Meeting

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.2475, up 17.80%, on 742,687 volume with 241 trades. The stock’s average daily volume over the past 60 days is 54,100, and its 52-week low/high is $0.005/$2.00.

Well Power Inc. (WPWR) has secured the US licensing rights to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and dilents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company is able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power Inc. delivers licensing fee

Well Power Inc. Closes First Round Of Funding

Well Power Inc. provides market update


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251